RxDoctor Payments Data

Ben Thomas

Family Medicine · Atlanta, GANPI 1497862593

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $658 of the $804 with a category attached, or 81.8%. Eli Lilly accounts for 81.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $708 and has fallen 97.8% since, to $16 in 2025.

$804in general payments, 2019–2025

Across 12 payments — averaging $67.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$658
  • AbbVie$70
  • Alkermes, Inc.$24
  • Novo Nordisk$19
  • Akcea Therapeutics, Inc.$18
  • Medline Industries LP$16
$3,167,333in research payments, 2019–2025

Across 232 payments — averaging $13,652 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.6M
  • Regeneron$449K
  • Pfizer$278K
  • Astrazeneca UK Limited$173K
  • Seqirus USA Inc$161K
  • Cue Health Inc.$145K
  • plus $335K from 9 others

What the payments were for

  • Travel & lodging$65882%
  • Food & beverage$14618%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$804 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia →

Other family medicine in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →